Sight Sciences Receives FDA Clearance for OMNI Ultra
Menlo Park, California – August 4, 2026 Sight Sciences, Inc. has announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Menlo Park, California – August 4, 2026 Sight Sciences, Inc. has announced that the U.S. Food and Drug Administration...
Ipswich, Massachusetts – August 4, 2026 New England Biolabs (NEB®) has expanded its molecular biology portfolio with the launch...
MONTEVIDEO, Uruguay & NEW YORK, United States, April 7, 2026 Resolve Therapeutics and the Institut Pasteur de Montevideo announced...
